Pure Global
NCT05501860

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Evaluation of the Ocular Safety of Articaine Sterile Topical Ophthalmic Solution
American Genomics, LLC·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Anesthesia, Local
Drug/Device/Intervention
AG-920
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
American Genomics, LLC
Location
Newport Beach,McAllen, United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Jul 30, 2022
End date
Dec 07, 2022
Enrollment
240 participants
Primary outcome

Number of participants with Treatment Emergent Adverse Events (TEAEs)

Summary

A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects.
 It is designed to evaluate the ocular safety of a single topical ocular administration of
 AG-920 sterile topical ophthalmic solution compared to placebo..

ICD-10 classifications
Local anaestheticsAnaesthetic, unspecifiedOther and unspecified general anaestheticsPoisoning: Local anaestheticsParenteral anaesthetics
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05501860
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05501860 through Pure Global AI's free database. This Phase 3 trial is sponsored by American Genomics, LLC and is currently Not yet recruiting. The study focuses on Anesthesia, Local. Target enrollment is 240 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.